Auristone is an Asian-based epigenomic profiling company powered with data analytics capabilities and extensive epigenomic know-how. We use our comprehensive portfolio of Asian epigenomic database to power data-driven drug and biomarker discoveries. EPI-Call™ is our Flagship second generation Next Generation Sequencing (NGS) test. In addition to genomic information (DNA-seq), EPI-Call™ further provides epigenomic information around the tumour micro-environment and predicts patient response to immunotherapy. EPI-Call™ is the pragmatic choice to aid physicians in deciding the best treatment option for their patients. We are committed to supporting clinical and academic epigenomic research, and moving such research outcomes into the clinical setting. Driven by our aspiration to improve the quality of life for patients through better treatment, we are continuously seeking ways to bring our technologies to our clinical and academic partners. For more information on the company, drop us a line at enquiry@auristone.com or visit our website at www.auristone.com.